Clinical Trial Update: First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT) [Phase 1, Phase 2]

View source ↗

Summary

A multicenter, open-label Phase Ib/II trial evaluating first-line trastuzumab with gemcitabine and cisplatin plus nivolumab in HER2-positive biliary tract cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Trastuzumab (trastuzumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Yonsei University | Conditions: HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer | Phase 1, Phase 2 | Status: RECRUITING